Norwegian Microemboli in Acute Stroke Study (NOR-MASS)
Norwegian Microemboli in Acute Stroke Study (NOR-MASS)
BACKGROUND: The cause of ischemic stroke remains undetermined in 30-40% of the cases, but circulating blood clots (thromboemboli) are a postulated common denominator in approx. 75% of patients. Transcranial Doppler monitoring (TCDM) is a non-invasive method of detecting circulating microemboli (CME) in the human cerebral circulation. The method is not used systematically in unselected groups of patients with repeated long-term registrations. New ultrasound equipment is ambulatory, less unpleasant for the patient and allows extended monitoring sessions. This may vastly simplify the implementation of TCDM as a clinically useful diagnostic tool.
AIMS: Determine the usefulness of TCDM in acute stroke diagnostics by assessing prevalence and frequency of CME in unselected patients with ischemic stroke, the influence of antithrombotic drugs on CME and the relationship between MES and recurrent stroke or transient ischemic attack (TIA).
HYPOTHESES: Prevalence and frequency of CME are higher during the first 24 hours than at later follow-up. Stroke etiology can be assessed by the presence or absence of CME. Presence of CME is associated with increased risk of recurrent TIA of stroke within 3 months and 1 year. Cessation of CME after the start of antithrombotic treatment is associated with reduced risk of recurrent TIA or stroke.
調査の概要
詳細な説明
- Standardized questionnaire
- Clinical work-up in accordance with hospital standard operating procedures, i.e. radiological and cardiological procedures, neurovascular ultrasound, clinical scoring, etc.
- 1st Transcranial Doppler monitoring (TCDM) at admission if within 24 hours after stroke onset (day 1). TCDM is repeated at 18-36 hours and at day 3. Microembolic signals are automatically registered by the software and subsequently verified manually.
研究の種類
入学 (予想される)
連絡先と場所
研究場所
-
-
-
Bergen、ノルウェー、5021
- 募集
- Haukeland University Hospital
-
コンタクト:
- Sander Aarli, MD
- 電話番号:+4799557918
- メール:drar@helse-bergen.no
-
コンタクト:
- Annette Fromm, MD, PhD
- メール:atfm@helse-bergen.no
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
サンプリング方法
調査対象母集団
説明
Inclusion Criteria:
- Admitted to hospital < 24 hours after onset of ischemic stroke
Exclusion Criteria:
- Temporal bone window inadequate for transcranial Doppler examination
- Participation in ongoing sonothrombolysis study (NOR-SASS 2)
- Reduced ability to cooperate
- No informed consent can be obtained
研究計画
研究はどのように設計されていますか?
デザインの詳細
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
時間枠 |
---|---|
Prevalence of circulating microemboli
時間枠:Up to 24 hours after symptom onset
|
Up to 24 hours after symptom onset
|
二次結果の測定
結果測定 |
時間枠 |
---|---|
Prevalence of circulating microemboli as a function of time and antithrombotic drugs
時間枠:3 days after symptom onset
|
3 days after symptom onset
|
Prevalence of MRI DWI lesions
時間枠:18-36 hours after symptom onset
|
18-36 hours after symptom onset
|
Recurrence of ischemic stroke/TIA
時間枠:3 months
|
3 months
|
協力者と研究者
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (予想される)
研究の完了 (予想される)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。